FCGR1A and tuberculosis: Together, these data suggest that FCGR1A could possibly serve as part of a reliable and robust predictive signature of the treatment response, and as such help optimizing personalized medicine in TB while minimizing de novo drug resistance, independent of age, immune status and genetic background.